Publications by authors named "Huaxin Shi"
Persistent infection of human papillomavirus (HPV) and immune escape are the main causes of cervical cancer. E6/E7 encoded by HPV16 may be closely related to carcinogenesis. HPV infection may upregulate PD-L1 expression, resulting in immune escape and cervical cancerigenesis.
View Article and Find Full Text PDFPrevious research suggested that Chinese Medicine (CM) Formula Huashibaidu granule might shorten the disease course in coronavirus disease 2019 (COVID-19) patients. This research aimed to investigate the early treatment effect of Huashibaidu granule in well-managed patients with mild COVID-19. An unblinded cluster-randomized clinical trial was conducted at the Dongxihu FangCang hospital.
View Article and Find Full Text PDFObjective: To evaluate the efficacy and safety of Hua Shi Bai Du Granule (Q-14) plus standard care compared with standard care alone in adults with coronavirus disease (COVID-19).
Study Design: A single-center, open-label, randomized controlled trial.
Setting: Wuhan Jinyintan Hospital, Wuhan, China, February 27 to March 27, 2020.
Ethnopharmacological Relevance: The coronavirus disease 2019 (COVID-19) has formed a global pandemic since late 2019. Benefitting from the application experience of Chinese Medicine (CM) for influenza and SARS, CM has been used to save patients at the early stage of COVID-19 outbreak in China.
Aim Of The Study: In order to evaluate the efficacy and safety of CM, and compare with Western Medicine (WM) for COVID-19, we conducted a retrospective case series study based on the patients in Wuhan Jinyintan Hospital, Wuhan, China.
Background: Treatments for coronavirus disease 2019 (COVID-19) are limited by suboptimal efficacy.
Methods: From January 30, 2020 to March 23, 2020, we conducted a non-randomised controlled trial, in which all adult patients with laboratory-confirmed COVID-19 were assigned to three groups non-randomly and given supportive treatments: Group A, Lopinavir-Ritonavir; Group B, Huashi Baidu Formula (a Chinese medicineformula made by the China Academy of Chinese Medical Sciences to treat COVID-19, which is now in the clinical trial period) and Lopinavir-Ritonavir; and Group C, Huashi Baidu Formula. The use of antibiotics, antiviruses, and corticosteroids was permitted in Group A and B.
Objective: To evaluate the effectiveness and safety of auricular acupoint bloodletting in treatment of insomnia METHODS: Participants (n = 60) with insomnia were randomized into two groups to receive treatment of auricular acupoint bloodletting: low frequency group, 1 times/week for five weeks (n = 30); high frequency group, 2times/week for two weeks (n = 30). The following outcomes were measured blindly at baseline, after first treatment, 4 weeks, and 8 weeks: Pittsburgh sleep quality index scale (PSQI).
Results: The groups were balanced at baseline for insomnia and demographic characteristics.
Objective: To evaluate the influence of clinical pathways in the hospitals using the Traditional Chinese Medicine in treatment of stroke in terms of postoperative complications, length of stay (LOS), costs incurred during hospitalization, compared with standard medical care.
Methods: Medline, Embase, China National Knowledge Infrastructure (CNKI) platforms, Wanfang databases and the Cochrane Central Register of Controlled Trials were searched. The search was performed up to August 2014.